The company Viriom presented an effective innovative drug for the treatment of HIV

Company "Viriom" presented data on the effectiveness of the innovative drug for the treatment of HIV in the Moscow International Week of Virology.

Developed by "Viriom" innovative drug VM-1500in clinical trials (CI) makes unique pharmacokinetic properties, and unlike other drugs of this class show a high efficiency, and resistance to HIV.

This was held at the "Moscow International week of Virology," said research director, Dr. Vadim Bychko.

Scientific and Practical Conference "International Week of Virology"— This is a global event that brings together leading scientists from Russia and the world to discuss the most important issues related to the development of new antiviral drugs, diagnostics and prevention of various viral infections. This year, the conference brought together about 100 top international experts in the field of virology from Western Europe and the United States. 

One of the key themes of the conference, given the global problems has become the fight against HIV. According to WHO and UNICEF in the world today is living with HIV about 34 million people, and this number is increasing annually by about 500,000 newly infected. Thanks to modern methods of therapy could significantly reduce mortality and increase the length and quality of life of infected patients. But the main task of scientists around the world — to develop a drug that completely destroys the virus. According to the head of the Moscow City Center for Prevention and Control of AIDS Alexei Mazus,
Russia has its own experience in dealing with this sensitive issue.

The company "Viriom" one of the first in the Russian Federation signed in 2009 a deal to license the technology transfer with the Swiss company «Hoffmann-La Roche» and won the right to develop and manufacture innovative candidate for the treatment of HIV / AIDS in Russia and the CIS. "Viriom" completed the program of preclinical studies and is currently conducting a number of Russian and international clinical ispytyny. The data indicate the superiority VM-1500efficacy and stability of the HIV virus to mutate over existing drugs in the same class.

In its report, "Safety, pharmacokinetics and efficacy of VM-1500, a new non-nucleoside reverse transcriptase inhibitor, in healthy volunteers and HIV-infected patients" Bychko doctor said that the results of the international clinical trials conducted in the Russian Federation and Thailand, VM-1500 drug is safe, well tolerated in healthy volunteers and patients with chronic HIV-1 infection in single and repeated oral administration, and has favorable pharmacokinetic properties.

Was shown clinical efficacy of the drug: a sharp drop in titers of HIV-1 (1.73 log10), nearing the maximum theoretically possible, all patients receiving the lowest dose (20 mg) daily for seven days. According to the results presented trials, the drug VM-1500 may be the best in its class.

"It was the first in Russia transfer deal involving Big Pharma, when the development was transferred to a Russian company for bringing it into production, so it is important that the primary clinical trials have confirmed the expectations of partners, and now there is a strong possibility that Russia might be the best in the world drug in this class, "- said the Chairman of the Board of Directors of the CHT" KhimRar " Andrey Ivashchenko.

The development of VM-1500 "Viriom" one of the first was supported by the Ministry of Industry and Trade of the Russian Federation within the framework of the Federal Program "Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and beyond."

Ltd. "Viriom" Company "Viriom" Center of High Technologies "KhimRar" develops innovative antiviral drugs and combinations of treatments and diagnostics. "Viriom" conducting research in Russia, using the experience and knowledge of Russian scientists and abroad with extensive international партнерства.Исследовательский Institute of Chemical Diversity is a key partner to conduct pre-clinical trials. Clinical studies conducted in Russia at the Moscow City Center for Prevention and Control of AIDS and the regional centers. International partners "Viriom" includes such companies and research organizations as Hoffmann-La Roche, Fox Chase Oncology Center, The Scripps Research Institute, Moscow Institute of Physics and Technology, Institute of Poliomyelitis and Viral Encephalitis, named after MP Chumakova.Proekt "Viriom "approved by the Commission on the modernization of the Presidential Federatsii.Moskovskaya International Week virusologiiMoskovskaya International Week of Virology was held from 8 to 12 September, with the support of the Department of Health of the city of Moscow, the Moscow City Center for Prevention and Control of AIDS, the Institute of Human Virology and the Global Virology network. On the scientific and practical conference brought together leading experts from around the world. Virologists discussed the latest scientific advances and emerging practices for infection control.

Like this post? Please share to your friends: